Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American ...

"The dosing of our first patient in the Phase 2 clinical trial of YA-101 for Multiple System Atrophy represents a big step forward as we strive to bring a much-needed treatment option to ...

Clinical practices and diagnostic challenges increase misdiagnoses Commonly revised diagnoses include vascular parkinsonism, progressive supranuclear palsy, multiple system atrophy, and clinically ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). "Following the positive ...